Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35839 | 0.81 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL1244050 | 0.81 | ALDH1A1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL170138 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL1635822 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL1201121 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL25416543 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL1083275 | 0.77 | — | — | |
| SCHEMBL728392 | 0.76 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL18660282 | 0.74 | TDP1 (0.33) | TDP1 | |
| SCHEMBL8927707 | 0.74 | FNTA (0.34) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630818-A | Protein-macromolecule conjugates and methods of use thereof | 北京轩义医药科技有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-109310981-A | Composite material, its preparation and gas purification purposes | 南洋理工大学 | 2019-02-05 | — | — | CN | claimed |
| EP-1922350-B1 | METHODS FOR PREPARING POLYMERIC REAGENTS | NEKTAR THERAPEUTICS (US) | 2015-01-07 | — | — | EP | claimed |
| US-8383380-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2013-02-26 | — | — | US | claimed |
| EP-1765411-B1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-06-20 | — | — | EP | claimed |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | NEKTAR THERAPEUTICS | 2012-04-12 | — | — | US | claimed |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2012-02-02 | — | — | US | claimed |
| US-8084572-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2011-12-27 | — | — | US | claimed |
| US-20110021761-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2011-01-27 | — | — | US | claimed |
| US-7834138-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-16 | — | — | US | claimed |
| JP-2007514761-A | — | — | 2007-06-07 | — | — | JP | claimed |
| EP-1694363-A2 | PEGYLATED SMALL MOLECULES | Nektar Therapeutics Al, Corporation (US) | 2006-08-30 | — | — | EP | claimed |
| US-20060183855-A1 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS AL, CORPORATION | 2006-08-17 | — | — | US | claimed |
| US-7053150-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-05-30 | — | — | US | claimed |
| WO-2005058367-A2 | PEGYLATED SMALL MOLECULES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050136031-A1 | Drugs covalently attached to a water-soluble oligomer; reduced first pass effect; e.g. non-opioid antagonist conjugated to a polyethylene glycol (PEG) group such as PEG-naloxol | REDHILL BIOPHARMA LTD. (IL) | 2005-06-23 | — | — | US | claimed |
| US-20040236015-A1 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS | 2004-11-25 | — | — | US | claimed |
| EP-0465302-B1 | Precursors of isocyanurate polymers having hydroxyl, urethane, isocyanate or acrylate groups, and process for their preparation | ATOCHEM ELF SA (FR) | 1994-12-28 | — | — | EP | claimed |
| US-4101461-A | Method for preparation of anion exchangers by substitution of hydrophilic polymeric gels | CZECHOSLOVENSKA AKADEMIE VED (CS) | 1978-07-18 | — | — | US | claimed |
| US-3991018-A | Method for preparation of cation exchangers by substitution of hydrophilic polymeric gels of crosslinked hydroxyalkyl acrylates and hydroxyalkylacrylamides | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021761-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | TDP1 1814/4885ALDH1A1 1185/4885TSHR 3620/4885 |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | TDP1 1814/4885ALDH1A1 1185/4885TSHR 3620/4885 |
| US-20050136031-A1 | Drugs covalently attached to a water-soluble oligomer; reduced first pass effect; e.g. non-opioid antagonist conjugated to a polyethylene glycol (PEG) group such as PEG-naloxol | OPRM1, OPRL1, OPRK1 | TDP1 4453/4885ALDH1A1 1511/4885TSHR 2306/4885 |
| US-20060183855-A1 | Segmented polymers and their conjugates | EPCAM, CD44, ECPAS | TDP1 1814/4885ALDH1A1 1185/4885TSHR 3620/4885 |
| US-20120088745-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, PLG | TDP1 4000/4885ALDH1A1 1403/4885TSHR 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.